Federated Hermes Inc. Boosts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Federated Hermes Inc. boosted its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 104.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,267,206 shares of the company's stock after purchasing an additional 1,157,006 shares during the period. Federated Hermes Inc. owned about 4.89% of Structure Therapeutics worth $92,411,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new position in Structure Therapeutics during the fourth quarter valued at $1,960,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Structure Therapeutics by 208.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company's stock worth $177,000 after acquiring an additional 2,939 shares during the period. Raymond James & Associates bought a new position in shares of Structure Therapeutics in the fourth quarter worth about $233,000. TrueMark Investments LLC bought a new position in Structure Therapeutics in the 4th quarter worth approximately $1,073,000. Finally, Wellington Management Group LLP boosted its stake in Structure Therapeutics by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 867,579 shares of the company's stock worth $43,743,000 after purchasing an additional 657,310 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Lifesci Capital reaffirmed an "outperform" rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Thursday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and a consensus price target of $85.71.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR traded up $0.18 during midday trading on Friday, reaching $36.36. 383,323 shares of the stock traded hands, compared to its average volume of 576,817. The stock has a market capitalization of $1.69 billion and a PE ratio of -43.81. The company's 50 day moving average is $40.55 and its 200 day moving average is $48.47. Structure Therapeutics Inc. has a one year low of $21.79 and a one year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. As a group, equities analysts forecast that Structure Therapeutics Inc. will post -0.98 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.